CONFIDENTIAL — APPROVED FOR PUBLIC RELEASE · BUREAU FILE COPY RECORDS CURRENT AS OF 29 MAY 2026 · DISTRIBUTION: UNRESTRICTED
VendorInvestigator Independent Testing Bureau · Public Records Division
DOCKET YEAR 2026 · VOL. II
35,156 SAMPLES ON FILE
No fee · No favor
Compound Evidence File
#EC-2026-0659

Superdrol Oil

Filed under Injectable Oils. The bureau holds 112 laboratory returns for this compound from 36 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.

Cross-Index

Subjects Shipping This Compound

36 SUBJECTS
SubjectGradeSamplesMeanMinMaxFirst seenLast seen
Tianjin Finder Chemical TFCCASE #VI-2026-0693 A 6 10.0 9.9 10.0 14 Nov 2025 16 Apr 2026
JEEP PeptidesCASE #VI-2026-0457 A 4 10.0 9.9 10.0 28 Dec 2025 25 Jun 2026
Flourishglobal PeptideCASE #VI-2026-0630 A 3 10.0 9.9 10.0 17 Mar 2026 10 Jun 2026
Chinese Peptide CompanyCASE #VI-2026-0184 A 3 10.0 9.9 10.0 17 Mar 2026 26 Jun 2026
Hybio PharmaceuticalCASE #VI-2026-0065 A 3 10.0 9.9 10.0 2 Feb 2026 5 Jul 2026
Thermo Fisher ScientificCASE #VI-2026-0142 A 3 10.0 10.0 10.0 25 May 2026 11 Jul 2026
QYAOBIOCASE #VI-2026-0861 A 2 10.0 10.0 10.0 23 Mar 2026 10 Jul 2026
PolyPeptide GroupCASE #VI-2026-0143 A 2 10.0 10.0 10.0 3 Dec 2025 2 Jul 2026
HomopeptideCASE #VI-2026-0760 A 4 9.9 9.9 10.0 25 May 2026 25 May 2026
BachemCASE #VI-2026-0314 A 4 9.9 9.9 10.0 23 Feb 2026 28 Jun 2026
Kerui PeptidesCASE #VI-2026-0626 A 4 9.9 9.9 10.0 22 Dec 2025 4 Jun 2026
AmbioPharmCASE #VI-2026-0177 A 4 9.9 9.9 10.0 19 Feb 2026 23 Jul 2026
Sangon BioCASE #VI-2026-0671 A 3 9.9 9.9 10.0 20 Nov 2025 1 Jul 2026
Shanghai Sigma AudleyCASE #VI-2026-0505 A 3 9.9 9.9 10.0 27 Mar 2026 19 Jun 2026
WuXi TIDESCASE #VI-2026-0335 A 3 9.9 9.9 9.9 25 Jan 2026 20 May 2026
GenScript PeptidesCASE #VI-2026-0860 A 3 9.9 9.9 10.0 25 Jan 2026 5 Aug 2026
AsymchemCASE #VI-2026-0091 A 3 9.9 9.9 9.9 17 Feb 2026 16 May 2026
Shanghai ERP BiotechnologyCASE #VI-2026-0936 A 2 9.9 9.9 10.0 28 Jan 2026 5 Jun 2026
Hubei JianxiangCASE #VI-2026-0048 A 2 9.9 9.9 10.0 1 May 2026 18 May 2026
Mokemei BiotechnologyCASE #VI-2026-0540 A 2 9.9 9.9 10.0 7 Mar 2026 6 Jun 2026
Shanghai Wibson BiotechnologyCASE #VI-2026-0379 A 2 9.9 9.9 9.9 24 Apr 2026 6 May 2026
Sigma-AldrichCASE #VI-2026-0829 A 2 9.9 9.9 10.0 27 Jun 2026 21 Jul 2026
SinoPepCASE #VI-2026-0387 A 2 9.9 9.9 10.0 28 Jun 2026 4 Jul 2026
Shanghai Sigma Audley SSACASE #VI-2026-0486 A 6 9.0 8.3 10.0 24 May 2026 24 May 2026
Glbiochem (Shanghai)CASE #VI-2026-0704 A 3 8.8 7.0 10.0 21 May 2026 21 May 2026
Qingdao Sigma Chemical QSCCASE #VI-2026-0538 A 5 8.7 6.8 10.0 23 May 2026 23 May 2026
Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 A 4 8.6 7.9 9.5 24 May 2026 24 May 2026
Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 A 8 8.3 7.0 9.3 23 May 2026 23 May 2026
Top PeptideCASE #VI-2026-0721 X 1 7.5 7.5 7.5 24 Apr 2025 24 Apr 2025
Nuscience PeptidesCASE #VI-2026-0554 X 3 7.2 5.7 9.5 20 Jun 2025 26 Jan 2026
InjectifyCASE #VI-2026-0387 X 2 7.2 5.9 8.4 8 Jul 2025 26 Jan 2026
Biolongevity LabsCASE #VI-2026-0442 X 1 6.5 6.5 6.5 24 Apr 2025 24 Apr 2025
Shanghai OuDaXin New Material Technology CenterCASE #VI-2026-0498 E 4 6.3 5.1 8.7 27 Feb 2025 19 Jan 2026
Zhejiang Yichenkang BiotechnologyCASE #VI-2026-0269 X 3 6.2 4.4 7.7 9 Jun 2025 19 Jan 2026
Heman Peptide HMCASE #VI-2026-0089 X 2 4.3 3.6 5.1 13 Jun 2025 17 May 2026
Peptide ArkCASE #VI-2026-0350 X 1 1.6 1.6 1.6 14 Jan 2025 14 Jan 2025

Open any subject to view the batch-level evidence for Superdrol Oil alone.